Emerging problems in the pharmacology of migraine: Interactions between triptans and drugs for prophylaxis

Pharmacological Research

Volumn 48, Issue 1, 2003, Pages 1-9

  Ferrari, A ^a,b   Sternieri, E ^a,b   Ferraris, E ^a,b   Bertolini, A ^a,b  

^a Centre for the Study of Headache   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Cytochromes P 450 (CYP); Drug drug interactions; Migraine; Prophylactic treatment of migraine; Triptans

Indexed keywords

AMITRIPTYLINE; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CIMETIDINE; CINNARIZINE; CITALOPRAM; DIGOXIN; ERGOT ALKALOID; FLUOXETINE; GABAPENTIN; HYDROCHLOROTHIAZIDE; LAMOTRIGINE; LORNOXICAM; METOPROLOL; NADOLOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PROPRANOLOL; RIFAMPICIN; RIZATRIPTAN; THEOPHYLLINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; ZOLMITRIPTAN;

BIOTRANSFORMATION; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LIVER METABOLISM; LIVER TOXICITY; MIGRAINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SIDE EFFECT; VASOSPASM;

EID: 0038627846     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(03)00095-1     Document Type: Review

References (49)

1. Ferrari M.D., Roon K.I., Lipton R.B., Goadsby P.J. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 358:2001;1668-1675.
2. Savani N., Brautaset N.J., Reunanen M., Szirmai I., Ashford E.A., Hassani H., Saiers J. A double-blind placebo-controlled study assessing the efficacy and tolerability of sumatriptan 50. mg tablets in the acute treatment of migraine. Sumatriptan Tablets S2CM07 Study Group Int. J. Clin. Pratt. 105(Suppl.):1999;7-15.
3. Visser W.H., de Vriend R.H., Jaspers M.W., Ferrari M.D. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology. 47(1):1996;46-51.
4. Rapoport A.M., Tepper S.J. Triptans are all different. Arch. Neurol. 58:2001;1479-1480.
5. Fleishaker J.C., Ryan K.K., Jansat J.M., Carel B.J., Bell D.J., Burke M.T., Azie N.E. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br. J. Clin. Pharmacol. 51(5):2001;437-441.
6. Diagnostic and therapeutic guidelines for migraine and cluster headache. J Headache Pain 2001;2:107-192.
7. Nelson D.R., Kamataki T., Waxman D.J., Guengerich F.P., Estabrook R.W., Feyereisen R., Gonzalez F.J., Coon M.J., Gunsalus I.C., Gotoh O.et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 12(1):1993;1-51.
8. Slaughter R.L., Edwards D.J. Recent advances: the cytochrome P450 enzymes. Ann. Pharmacother. 29:1995;619-624.
9. Liston H.L., Markowitz J.S., DeVane C.L. Drug glucuronidation in clinical psychopharmacology. J. Clin. Psychopharmacol. 21(5):2001;500-515.
10. Tanaka E. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J. Clin. Pharm. Ther. 24(2):1999;87-92.
11. Wen X., Wang J.S., Kivisto K.T., Neuvonen P.J., Backman J.T. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytocrome P450 2C9 (CYP 2C9). Br. J. Clin. Pharmacol. 52(5):2001;547-553.
12. Lin Jh., Lu A.Y. Interindividual variability in inhibition and induction of cytocrome P450 enzymes. Ann. Rev. Pharmacol. Toxicol. 41:2001;535-567.
13. Lin Jh., Lu A.Y. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35(5):1998;361-390.
14. Alvan G., Bechtel B., Iselius L., Gundert-Remy U. Hydroxilation polymorphism of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharm. 39:1990;533-537.
15. Sohn D.R., Shin S.G., Park C.W., Kusaka M., Chiba K., Ishizaki T. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br. J. Clin. Pharm. 32:1991;504-507.
16. Bertilsson L. Geografical/interracial differences in polymorphic drug oxidation. Clin. Pharmacokinet. 29:1995;192-209.
17. Dresser G.K., Spence J.D., Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Chin. Pharmacokinet. 38(1):2000;41-57.
18. Ingelman-Sundberg M., Oscarson M., McLellan R.A. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci. 20(8):1999;342-349.
19. Campbell M.E., Speilberg S.P. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin. Pharm. Ther. 42:1987;157-165.
20. Rowland M., Matin S.B. Kinetics of drug-drug interaction. J. Pharmacokinet. Biopharm. 1:1973;553-567.
21. Berenbaum M.C. The expected effect of a combination of agents. J. Theor. Biol. 114:1985;413-431.
22. ® Healthcare series Database, vol. 112. Expires July 2002.
23. Caraco Y. Genetic determinants of drug responsiveness and drug interactions. Ther. Drug Monit. 20(5):1998;517-524.
24. Lennard M.S. Genetically determined adverse drug reactions involving metabolism. Drug Saf. 9(1):1993;60-77.
25. Michalets E.L. Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy. 18(1):1998;84-112.
26. Masubuchi Y., Hosokawa S., Horie T., Suzuki T., Ohmori S., Kitada M.et al. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desiopropylase. Drug Metab. Dispos. 22(6):1994;909-915.
27. Yashimoto K., Echizen H., Chiba K., Tani M., Ishizaki T. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers N-desisopropylation is mediated mainly by CYP1A2. Br. J. Clin. Pharmacol. 39(4):1995;421-431.
28. McGinnity D.F., Parker A.J., Soars M., Riley R.J. Automated definition of the enzymology of drug oxidation by the major human drug metabolising cytochrome P450s. Drug Metab. Dispos. 28(11):2000;1327-1334.
29. Preskorn S.H., Magnus R.D. Inhibition of hepatic P450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol. Bull. 30(2):1984;251-259.
30. Kobayashi K., Ishizuka T., Shimada N., Yoshimura Y., Kamijima K., Chiba K. Sertraline N-demethylation is catalysed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab. Dispos. 27(7):1999;763-766.
31. Von Moltke L.L., Greenblatt D.J., Duan S.X., Schmider J., Kudchadker L., Fogelman S.M.et al. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology. 128(4):1996;398-407.
32. Busse D., Cosme J., Beaune P., Kroemer H.K., Eichelbaum M. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation verapamil in humans. Naunyn-Schmiedeberg's Arch Pharmacol. 353(1):1995;116-121.
33. Olesen O.V., Linnet K. Metabolism the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology. 55(5):1997;235-243.
34. Venkatakrishnan K., Greenblatt D.J., von Moltke L.L., Schmider J., Harmatz J.S., Shader R.I. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance CYP 2C19 and 3A4. J. Clin. Pharmacol. 38(2):1998;112-121.
35. Rosenfeld W.E., Doose D.R., Walker S.A., Nayak R.K. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia. 38(3):1997;317-323.
36. Perucca E., Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin. Pharmacokinetic. 31(1):1996;29-46.
37. Bailey D.G., Malcolm J., Arnold O., Spence J.D. Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol. 46(2):1998;101-110.
38. Silva J.M., Morin P.E., Day S.H., Kennedy B.P., Payette P., Rushmore T.et al. Refinement of an in vitro cell model cytochrome P450 induction. Drug Metab. Dispos. 26(5):1998;490-496.
39. Tabakoff B., Hoffman P.L. Alcohol addiction: an enigma among us. Neuron. 16(5):1996;909-912.
40. Millson D.S., Tepper S.J., Rapoport A.M. Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. Expert Opin. Pharmacother. 1(3):2000;391-404.
41. Fowler P.A., Lacey L.F., Thomas M., Keene O.N., Tanner R.J.N., Baber N.S. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur. Neurol. 31:1991;291-294.
42. Vyas K.P., Halpin R.A., Geer L.A., Ellis J.D., Liu L., Cheng H.et al. Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. Drug Metab. Dispos. 28:2000;89-95.
43. Rolan P. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig™, 311C90). Cephalalgia. 18(Suppl):1997;21-27.
44. Rabasseda X. Almotriptan in the treatment of migraine. Drugs Today. 37(1):2001;5-21.
45. Cole P., Rabasseda X. Migraine headache treatment with eletriptan, a second-generation serotonin receptor agonist. Drugs Today. 37(3):2001;159-171.
46. Eletriptan, Product Monograph, New York: Pfizer Inc.; September 2001.
47. Comer M.B. Pharmacology of the selective 5-HT 1B/1D agonist. Frovatriptan: heazdache. 42(Suppl 2):2002;S47-S53.
48. Buchan P., Wade A., Ward C., Oliver S.D., Stewart A.J., Freestone S. Frovatriptan: a review of drug-drug interactions. Headache. 42(Suppl. 2):2002;S63-S73.
49. Tfelt-Hansen P., De Vries P., Saxena P.R. Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 60(6):2000;1259-1287.